Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RLMD vs COCP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RLMD Captures Overall Composite Edge (35.3 SELL vs 47.1 HOLD), While COCP Leads 3–2 on Growth & Valuation Pillars

RLMD Overall Winner 6-Pillar Tally: RLMD 2 – 3 COCP (1 Tie) Matrix Metrics: RLMD 3 – 4 COCP

As of Nov 16, 2026, Relmada Therapeutics, Inc. (RLMD) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (35.3/100 SELL vs. 47.1/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. RLMD trades at $3.62 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.00 (N/M Forward P/E, -3063.6% operating margin).

  • Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. RLMD 35.3/100 SELL), RLMD captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3063.6% operating margin) and revenue trajectory (+0.0% vs. +26.9% YoY).
  • Technical & Structure Timing Caution: RLMD is currently in a Breakdown options structure phase (RSI 45.9); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RLMD vs COCP
RLMD NASDAQ Head-to-Head Winner
Relmada Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.62
-14.01% 1D
Market Cap $421.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.58β · 93% Vol
Unified Composite Score
35.3 / 100 SELL
Tech 50.0 Fund 34.0 Flow 71.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.9 · SMA20: $3.74 · SMA50: $3.75
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.99% 1D
Market Cap $19.6M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 1.24β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $1.00 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (RLMD 2 – 3 COCP)

Columns: Metric · RLMD · COCP
1. Valuation Multiples COCP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 49.7x
2. Growth & Scale COCP
Revenue Growth (YoY) +0.0% +26.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $330,000
Market Cap $421.3M $19.6M
3. Profitability & Quality RLMD
Gross Margin N/A N/A
Operating Margin 0.0% -3063.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -64.7% -311.7%
4. Balance Sheet & Cash Flow COCP
Cash Generation (TTM) -$46M -$7.6M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.94 Book/Sh · -64.7% ROE $3.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RLMD
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 93.2% (36th %ile) N/A (N/A)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RLMD (3) vs COCP (4)
Institutional Metric RLMD COCP Criterion Row Edge
Market Capitalization
Scale
$421.3M $19.6M Larger Scale RLMD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +26.9% Higher Growth COCP
Operating Margin (TTM)
Profitability
0.0% -3063.6% Higher Margin RLMD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-64.7% -311.7% Higher ROE RLMD
52-Week Range Position
Momentum
11% ($3–$8) 19% ($1–$2) Stronger Trend COCP
Beta / 30D Volatility
Risk Regime
1.58β · 93% Vol 1.24β · 54% Vol Lower Realized Risk COCP
Unified Institutional Score
Composite Signal
35.3 / 100 (SELL) 47.1 / 100 (HOLD) Higher Composite COCP
Trailing 12M Revenue (USD)
Operating Scale
N/A $330,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 49.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$46M ($1.94 Book/Sh · -64.7% ROE) -$7.6M ($3.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RLMD +18.77 pp
RLMD: +16.77% · COCP: -2.0%
3M Horizon COCP +17.92 pp
RLMD: -25.36% · COCP: -7.44%
6M Horizon COCP +27.61 pp
RLMD: -42.9% · COCP: -15.29%
1Y Horizon COCP +3.75 pp
RLMD: -6.7% · COCP: -2.95%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RLMD Revenue COCP Revenue RLMD Op. Margin COCP Op. Margin Margin Leader
FY2011 N/A $10M N/A -30.6% COCP
FY2012 $0M N/A -151.8% N/A RLMD
FY2013 $0M N/A -877.7% N/A RLMD
FY2019 N/A $10M N/A -737.4% COCP
FY2020 N/A $0M N/A -476.0% COCP

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RLMD BREAKDOWN
134d in phase · OBV ACCUMULATION
Current IV 93.2%
IV Percentile 36th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RLMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RLMD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $421.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $19.6M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RLMD vs COCP Key Questions & Quantitative Answers

As of Nov 16, 2026, Relmada Therapeutics, Inc. (RLMD) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (35.3/100 SELL vs. 47.1/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. RLMD trades at $3.62 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.00 (N/M Forward P/E, -3063.6% operating margin). Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. RLMD 35.3/100 SELL), RLMD captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3063.6% operating margin) and revenue trajectory (+0.0% vs. +26.9% YoY). Technical & Structure Timing Caution: RLMD is currently in a Breakdown options structure phase (RSI 45.9); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

COCP leads the Growth & Scale pillar: RLMD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). Across the 5-period historical trajectory (FY2011 to FY2020), RLMD cumulative revenue shifted N/A while COCP shifted +0.0%. In operating R&D and SG&A reinvestment, RLMD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.

COCP screens cheaper on headline valuation multiples. RLMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RLMD (-64.7% ROE) versus COCP (-311.7% ROE) capital efficiency.

In options market volatility and institutional positioning, RLMD carries 93.2% implied volatility (36th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.58β · 93% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.24β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.